Congenital Bleeding Disorders and COVID-19 - An Emphasis on the Role of Thrombosis as One of the Main Causes of Morbidity and Mortality in COVID-19 / Akbar Dorgalaleh, Fatemeh Narouei, Mansur Asadi, Hassan Morovati Khamsi, Mohammad Saeed Gholami
A turbulent coagulation system is a prominent feature of Coronavirus Disease 2019 (COVID-19), with venous thromboembolism (VTE) a leading cause of death. Our hypothesis is that patients with inherited hypocoagulability, like congenital bleeding disorders (CBD), enjoy a protective effect against COVID-19-induced hypercoagulability and related fatal consequences. Our primary and follow-up observations revealed this effect, at least among patients with moderate to severe congenital bleeding disorders, particularly coagulation factor deficiencies. Theoretically, patients with inherited hypocoagulobility have only a potential protective effect against COVID-19-related hypercoagulability. Yet the lower rate of morbidity and mortality in patients with CBDs suggests that hypercoagulability and thrombotic events are the main cause of death in COVID-19. Therefore, appropriate and timely administration of anticoagulants could significantly decrease the rate of morbidity and mortality in COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological disorders, drug targets - 22(2023), 2, Seite 4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dorgalaleh, Akbar [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (4 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011164131 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011164131 | ||
| 003 | DE-627 | ||
| 005 | 20231128075707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011164131 | ||
| 035 | |a (KFL)prod_DARH_.A68DF8B1AF16E650123D142A8F67A7D0494558FC | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Dorgalaleh, Akbar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Congenital Bleeding Disorders and COVID-19 - An Emphasis on the Role of Thrombosis as One of the Main Causes of Morbidity and Mortality in COVID-19 |c Akbar Dorgalaleh, Fatemeh Narouei, Mansur Asadi, Hassan Morovati Khamsi, Mohammad Saeed Gholami |
| 264 | 1 | |c 2023 | |
| 300 | |a 1 Online-Ressource (4 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a A turbulent coagulation system is a prominent feature of Coronavirus Disease 2019 (COVID-19), with venous thromboembolism (VTE) a leading cause of death. Our hypothesis is that patients with inherited hypocoagulability, like congenital bleeding disorders (CBD), enjoy a protective effect against COVID-19-induced hypercoagulability and related fatal consequences. Our primary and follow-up observations revealed this effect, at least among patients with moderate to severe congenital bleeding disorders, particularly coagulation factor deficiencies. Theoretically, patients with inherited hypocoagulobility have only a potential protective effect against COVID-19-related hypercoagulability. Yet the lower rate of morbidity and mortality in patients with CBDs suggests that hypercoagulability and thrombotic events are the main cause of death in COVID-19. Therefore, appropriate and timely administration of anticoagulants could significantly decrease the rate of morbidity and mortality in COVID-19 | ||
| 700 | 1 | |a Narouei, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Asadi, Mansur |e verfasserin |4 aut | |
| 700 | 1 | |a Khamsi, Hassan Morovati |e verfasserin |4 aut | |
| 700 | 1 | |a Gholami, Mohammad Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological disorders, drug targets |d Sharjah [u.a.] : Bentham Science Publ., 2006 |g 22(2023), 2, Seite 4 |h Online-Ressource |w (DE-627)KFL009637397 |w (DE-600)2254232-2 |w (DE-576)273891057 |x 2212-4063 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:2 |g pages:4 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-529X&volume=22&issue=2&spage=83 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 2 |h 4 | ||